Literature DB >> 25952572

Biphenotypic hepatic tumors: imaging findings and review of literature.

Michael L Wells1, Sudhakar K Venkatesh2, Vishal S Chandan3, Jeff L Fidler1, Joel G Fletcher1, Geoffrey B Johnson1, David M Hough1, Lewis R Roberts4.   

Abstract

PURPOSE: To describe imaging findings in biphenotypic hepatic tumors (BPT) and a proposal for new imaging classification based on contrast-enhanced imaging.
METHODS: Retrospective review of CT, MRI, PET/CT, and ultrasound findings in 39 patients with histologically confirmed BPT was performed. Tumor markers including AFP, L3 fraction, CA 19.9, CA 125, and CEA were recorded. Based on the dynamic enhancement features, BPT were categorized into 4 enhancement patterns (Types 1-4). Enhancement patterns were correlated with other imaging findings and tumor markers. Imaging features and tumor markers that were not consistent with diagnosis of hepatocellular carcinoma or intrahepatic cholangiocarcinoma based on enhancement pattern were considered discordant findings.
RESULTS: Enhancement patterns in 29 patients (CT/MR) included 23 Type 2 (continuous peripheral rim of late arterial hyperenhancement with washout or fade in portal venous and/or delayed phases, ±delayed central enhancement) and 2 of each Types 1, 2, and 3. Discordant imaging findings were present in two patients with Type 2 pattern and in one patient with Type 1 pattern. Both AFP and CA 19.9 were elevated in 15 of 33 of patients. Tumor markers AFP and CA 19.9 were discordant in 17 of 21 patients with Type 2 pattern, two of two patients with Type 3 pattern. Most BPTs were markedly PET avid with average SUV max of 8.2. Most frequent ultrasound appearance is peripheral hypoechogenicity and central hyperechogenicity.
CONCLUSIONS: BPT most commonly present with imaging features similar to cholangiocarcinoma or metastases. BPT can be suggested when imaging findings or tumor markers are discordant with the most likely diagnosis based on enhancement pattern.

Entities:  

Keywords:  Biphenotypic hepatic tumor; Computed tomography (CT); Magnetic resonance imaging (MRI); Positron emission tomography (PET); Ultrasound (US)

Mesh:

Substances:

Year:  2015        PMID: 25952572     DOI: 10.1007/s00261-015-0433-9

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  14 in total

1.  cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.

Authors:  Elizabeth Brunt; Shinichi Aishima; Pierre-Alain Clavien; Kathryn Fowler; Zachary Goodman; Gregory Gores; Annette Gouw; Alex Kagen; David Klimstra; Mina Komuta; Fukuo Kondo; Rebecca Miksad; Masayuki Nakano; Yasuni Nakanuma; Irene Ng; Valerie Paradis; Young Nyun Park; Alberto Quaglia; Massimo Roncalli; Tania Roskams; Michiie Sakamoto; Romil Saxena; Christine Sempoux; Claude Sirlin; Ashley Stueck; Swan Thung; W M S Tsui; Xin-Wei Wang; Aileen Wee; Hirohisa Yano; Matthew Yeh; Yoh Zen; Jessica Zucman-Rossi; Neil Theise
Journal:  Hepatology       Date:  2018-05-09       Impact factor: 17.425

2.  Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.

Authors:  Yeun-Yoon Kim; Chansik An; Sungwon Kim; Myeong-Jin Kim
Journal:  Eur Radiol       Date:  2017-12-11       Impact factor: 5.315

3.  Management of combined hepatocellular carcinoma-cholangiocarcinoma.

Authors:  Ju Dong Yang; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2018-10-17

Review 4.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Authors:  An Tang; Mustafa R Bashir; Michael T Corwin; Irene Cruite; Christoph F Dietrich; Richard K G Do; Eric C Ehman; Kathryn J Fowler; Hero K Hussain; Reena C Jha; Adib R Karam; Adrija Mamidipalli; Robert M Marks; Donald G Mitchell; Tara A Morgan; Michael A Ohliger; Amol Shah; Kim-Nhien Vu; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-21       Impact factor: 11.105

5.  Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.

Authors:  Tyler J Fraum; Roberto Cannella; Daniel R Ludwig; Richard Tsai; Muhammad Naeem; Maverick LeBlanc; Amber Salter; Allan Tsung; Anup S Shetty; Amir A Borhani; Alessandro Furlan; Kathryn J Fowler
Journal:  Eur Radiol       Date:  2019-10-25       Impact factor: 5.315

6.  Diagnostic performance of the LR-M criteria and spectrum of LI-RADS imaging features among primary hepatic carcinomas.

Authors:  Seung-Seob Kim; Sunyoung Lee; Jin-Young Choi; Joon Seok Lim; Mi-Suk Park; Myeong-Jin Kim
Journal:  Abdom Radiol (NY)       Date:  2020-11

Review 7.  Combined Hepatocellular-Cholangiocarcinoma: Changes in the 2019 World Health Organization Histological Classification System and Potential Impact on Imaging-Based Diagnosis.

Authors:  Tae Hyung Kim; Haeryoung Kim; Ijin Joo; Jeong Min Lee
Journal:  Korean J Radiol       Date:  2020-07-27       Impact factor: 3.500

8.  Differentiation combined hepatocellular and cholangiocarcinoma from intrahepatic cholangiocarcinoma based on radiomics machine learning.

Authors:  Jun Zhang; Zixing Huang; Likun Cao; Zhen Zhang; Yi Wei; Xin Zhang; Bin Song
Journal:  Ann Transl Med       Date:  2020-02

9.  MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma.

Authors:  Jennifer Sammon; Sandra Fischer; Ravi Menezes; Hooman Hosseini-Nik; Sara Lewis; Bachir Taouli; Kartik Jhaveri
Journal:  Cancer Imaging       Date:  2018-02-27       Impact factor: 3.909

10.  Imaging performance and clinical value of contrast-enhanced ultrasonography and computed tomography in the diagnosis of liver cancer.

Authors:  Bolin Sun; Yongbin Lv; Dong Xing; Jianlin Li
Journal:  Oncol Lett       Date:  2018-03-15       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.